Literature DB >> 17545546

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.

Elias Drakos1, Athanasios Thomaides, L Jeffrey Medeiros, Jiang Li, Vasiliki Leventaki, Marina Konopleva, Michael Andreeff, George Z Rassidakis.   

Abstract

PURPOSE: p53 is frequently expressed but rarely mutated in Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin's lymphoma (HL). p53 protein levels are regulated by murine double minute 2 (MDM2) through a well-established autoregulatory feedback loop. In this study, we investigated the effects of nutlin-3A, a recently developed small molecule that antagonizes MDM2 and disrupts the p53-MDM2 interaction, on p53-dependent cell cycle arrest and apoptosis in cultured HRS cells. EXPERIMENTAL
DESIGN: HL cell lines carrying wild-type (wt) or mutated p53 gene were treated with the potent MDM2 inhibitor nutlin-3A or a 150-fold less active enantiomer, nutlin-3B.
RESULTS: We show that nutlin-3A, but not nutlin-3B, stabilizes p53 in cultured HRS cells carrying wt p53 gene resulting in p53-dependent cell cycle arrest and apoptosis. Cell cycle arrest was associated with up-regulation of the cyclin-dependent kinase inhibitor p21. Nutlin-3A-induced apoptotic cell death was accompanied by Bax and Puma up-regulation and caspase-3 cleavage and was abrogated, in part, by inhibition of caspase-9 and caspase-3 activity. By contrast, no effects on cell cycle or apoptosis were found in HL cell lines harboring mutated p53 gene. Furthermore, combined treatment with nutlin-3A and doxorubicin revealed enhanced cytotoxicity in HRS cells with wt p53 gene. Blocking of nuclear export by leptomycin B, or inhibition of proteasome by MG132, stabilized p53 at a level comparable with that of nutlin-3A treatment in HRS cells with wt p53.
CONCLUSIONS: These data suggest that nutlin-3A stabilized p53 by preventing MDM2-mediated p53 degradation in HRS cells. wt p53 stabilization and activation by nutlin-3A may be a novel therapeutic approach for patients with HL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545546     DOI: 10.1158/1078-0432.CCR-06-2581

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  A stapled p53 helix overcomes HDMX-mediated suppression of p53.

Authors:  Federico Bernal; Mark Wade; Marina Godes; Tina N Davis; David G Whitehead; Andrew L Kung; Geoffrey M Wahl; Loren D Walensky
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

2.  HDM2 promotes WIP1-mediated medulloblastoma growth.

Authors:  Meghan C Buss; Tracy-Ann Read; Matthew J Schniederjan; Khanjan Gandhi; Robert C Castellino
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

3.  Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.

Authors:  Manujendra N Saha; Hua Jiang; Hong Chang
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

4.  Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.

Authors:  Tianli He; Jiayou Guo; Hongmei Song; Hongcheng Zhu; Xiaoke Di; Hua Min; Yuandong Wang; Guangzong Chen; Wangshu Dai; Jianhua Ma; Xinchen Sun; Jianxin Ma
Journal:  Pathol Oncol Res       Date:  2017-03-24       Impact factor: 3.201

Review 5.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 6.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

Authors:  Yoko Tabe; Denise Sebasigari; Linhua Jin; Martina Rudelius; Theresa Davies-Hill; Kazunori Miyake; Takashi Miida; Stefania Pittaluga; Mark Raffeld
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.

Authors:  Ting-Yun Liu; Shang-Ju Wu; Mi-Hsin Huang; Fei-Yun Lo; Mong-Hsun Tsai; Ching-Hwa Tsai; Su-Ming Hsu; Chung-Wu Lin
Journal:  Mol Cancer       Date:  2010-02-09       Impact factor: 27.401

9.  Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.

Authors:  Richard J Jones; Qing Chen; Peter M Voorhees; Ken H Young; Nathalie Bruey-Sedano; Dajun Yang; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

10.  An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Authors:  Ramzi M Mohammad; Jack Wu; Asfar S Azmi; Amro Aboukameel; Angela Sosin; Sherwin Wu; Dajun Yang; Shaomeng Wang; Ayad M Al-Katib
Journal:  Mol Cancer       Date:  2009-12-03       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.